Table 1.
Summary of the included studies
| ID | Centers | Sample size, (EID/SID), n | Year of recruitment | Study design | Groups | Outcomes |
|---|---|---|---|---|---|---|
| Bomprezzi [33] | Vanderbilt University Medical Center and Barrow | 96/361 | September 2006 to April 2013 | Retrospective cohort | Two different groups | Relapses and MRI activity |
| Butzkueven [23] | Tysabri Observational Program | 219/219 | 2014 to November 2019 | Retrospective cohort | Two different groups | ARR, and confirmed disability worsening |
| Chisari [34] | Italian MS Register | 838/1254 | 1 June 2012 to 15 May 2018 | Retrospective multicenter | Two different groups | Relapses, EDSS, ARR, NEDA-2, Progression index, and Confirmed disability improvement |
| De Mercanti [35] | 14 Italian MS centers | 129/187 | March 2007 to March 2018 | Retrospective multicenter | Two different groups | MRI activity |
| Foley [4] | 89 multiple sclerosis centers across11 countries in the Americas, Europe, and Western Pacific | 247/242 | – | Randomized, controlled, open-label, phase 3b trial (NOVA) | Two different groups | Relapses, ARR, and MRI activity |
| Jeantin [39] | Monocentric, (Observatoire Français de la Sclérose en plaques, OFSEP) database | 57/57 | 2020 | Retrospective, self-controlled | Pre vs post switch | Relapses, MRI activity |
| Pelle [40] | 5 different Frensh centers; Caen, Nice, Bobigny and Toulouse hospitals as well as Percy Military Hospital | 147/156 | 2020 | Retrospective multicenter | Two different groups | Relapses, EDSS, ARR, MRI activity, anti-JCV index |
| Riancho [36] | Sierrallana, in Cantabria, Spain | 39/39 | – | Retrospective cohort | Pre vs post switch | ARR, radiological activity, disability progression, and NEDA-3 |
| Ryerson [37] | 9 US MS centers | 894/1080 | 2004 | Retrospective cohort | Two different groups | Relapses, MRI activity, and ARR |
|
Ryerson [17] (primary) Ryerson [17] (secondary) Ryerson [17] (tertiary) |
TOUCH database-Biogen’s Tysabri Global Safety Database |
1988/13,132 3331/15,424 815/23,168 |
February 2012 to June 2017 | Retrospective cohort | Two different groups | PML |
| Ryerson [32] | TOUCH data (7 US sites) | 79/354 | Jul-20 | Retrospective cohort | Two different groups | MRI activity |
| Trojano [21] | Belgium, Germany, Spain, France, and Italy | 52/54 | Dec-10 | RCT | Two different groups | Relapses, MRI activity, and confirmed disability worsening |
| Van Kempen [38] | 4 hospitals in Netherlands | 51/10 | November 2015 to June 2018 | Prospective multicenter single arm | Pre vs post switch | MRI activity, relapses and EDSS |
| Yamout [22] | Lebanon–Iran | 85/85 | – | Retrospective review study of prospectively followed cohorts | Pre vs post switch | EDSS, ARR, relapses, MRI activity and disability progression |
EID extended interval dosing, SID standard interval dosing, MS multiple sclerosis, PML progressive multifocal leukoencephalopathy, EDSS Expanded Disability Status Scale, ARR annualized relapse rate, NEDA no evidence of disease activity, RCT randomized controlled trial